Inverse Probability; Confidence Limits

1992 ◽  
pp. 102-117
Author(s):  
Byron P. Roe
Keyword(s):  
Confidence Limits ◽  
Inverse Probability

scholarly journals Impact of Adopting Improved Seeds on Access to Broader Food Groups Among Small-Scale Sorghum Producers in Tanzania

SAGE Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 215824402097999
Author(s):  
Aloyce R. Kaliba ◽  
Anne G. Gongwe ◽  
Kizito Mazvimavi ◽  
Ashagre Yigletu
Keyword(s):  
Food Security ◽  
Dietary Diversity ◽  
Sampling Technique ◽  
Inverse Probability Weighting ◽  
Reproductive Age ◽  
Small Scale ◽  
Probability Weighting ◽  
Food Groups ◽  
Inverse Probability ◽  
Double Robust

In this study, we use double-robust estimators (i.e., inverse probability weighting and inverse probability weighting with regression adjustment) to quantify the effect of adopting climate-adaptive improved sorghum varieties on household and women dietary diversity scores in Tanzania. The two indicators, respectively, measure access to broader food groups and micronutrient and macronutrient availability among children and women of reproductive age. The selection of sample households was through a multistage sampling technique, and the population was all households in the sorghum-producing regions of Central, Northern, and Northwestern Tanzania. Before data collection, enumerators took part in a 1-week training workshop and later collected data from 822 respondents using a structured questionnaire. The main results from the study show that the adoption of improved sorghum seeds has a positive effect on both household and women dietary diversity scores. Access to quality food groups improves nutritional status, food security adequacy, and general welfare of small-scale farmers in developing countries. Agricultural projects that enhance access to improved seeds are, therefore, likely to generate a positive and sustainable effect on food security and poverty alleviation in sorghum-producing regions of Tanzania.

Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: A plasmode simulation

2021 ◽  
Vol 40 (9) ◽  
pp. 2101-2112
Author(s):  
Mitchell M. Conover ◽  
Kenneth J. Rothman ◽  
Til Stürmer ◽  
Alan R. Ellis ◽  
Charles Poole ◽  
...  
Keyword(s):  
Measurement Error ◽  
Propensity Score ◽  
Inverse Probability ◽  
Covariate Measurement Error

scholarly journals Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring

Biometrics ◽  
2021 ◽  
Author(s):  
Sujatro Chakladar ◽  
Samuel P. Rosin ◽  
Michael G. Hudgens ◽  
M. Elizabeth Halloran ◽  
John D. Clemens ◽  
...  
Keyword(s):  
Inverse Probability ◽  
Partial Interference ◽  
Inverse Probability Weighted

EXPRESS: Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: A nationwide cohort study

2021 ◽  
pp. 174749302110294
Author(s):  
Peter Nielsen ◽  
Mette Soegaard ◽  
Martin Jensen ◽  
Anne G Ording ◽  
Gregory Lip
Keyword(s):  
Atrial Fibrillation ◽  
Confidence Intervals ◽  
Stroke Prevention ◽  
Clinical Care ◽  
Bleeding Events ◽  
Inverse Probability ◽  
Standard Clinical Practice ◽  
Hazard Ratios ◽  
All Cause Mortality ◽  
Event Rates

Background and purpose: The effectiveness and safety of edoxaban 60 mg and 30 mg for stroke prevention compared with warfarin in patients with atrial fibrillation (AF) has not been well-described in a nationwide cohort of Caucasian patients treated in standard clinical practice. Methods: We used Danish nationwide registries to identify patients with AF during June 2016 and November 2018 who were treated with edoxaban or warfarin and computed rates per 100 person-years of thromboembolic, all-cause mortality, and bleeding events using an inverse probability of treatment weighting approach to account for baseline confounding. We used weighted pooled logistic regression to compute hazard ratios (HRs) with 95% confidence intervals (CIs) comparing events between edoxaban 60 mg and warfarin users; edoxaban 30 mg was not included in formal comparisons. Results: We identified 6451 AF patients, mean age was 72 years and 40% were females. A total of 1772 patients were treated with edoxaban 60 mg, 537 with edoxaban 30 mg, and 4142 with warfarin. The median CHA2DS2-VASc score was similar between warfarin and edoxaban 60 mg with a score of 3 (interquartile range [IQR] 2-4). In the inverse probability of treatment-weighted pseudo-population, the thromboembolic event rate for edoxaban 60 mg was 0.95 and 1.0 for warfarin, corresponding weighted HR of 1.00 (95% confidence intervals [CI] 0.59, 1.71). Edoxaban 60 mg users were associated with lower rates of all-cause mortality (3.93) compared to warfarin (6.04), with a HR of 0.64 (95% CI 0.47 to 0.88). The event rates for bleeding were 3.36 and 3.14, respectively; HR 1.09 (95% CI 0.77, 1.57) Conclusion: Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for white European patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality. 

Sign in / Sign up

Export Citation Format

Share Document